Our real-world data-based study identifies drugs that might have a potential beneficial effect (levothyroxine, mirabegron and ropinirole) and a potential adverse effect (levetiracetam and quetiapine) in AD in patients with neuroinflammation-related conditions such as alcohol use disorder (AUD), epilepsy, hemorrhagic stroke (HS), and traumatic brain injury (TBI).
